Back

Clinical, genetic, and prognostic implications of illicit drug use in dilated cardiomyopathy

9 May 2026 (13:30 - 14:15)
Organised by: Logo
Congress Presentation Part of: Socioeconomics and regional heterogeneity of heart failure Epidemiology, Prognosis, Outcome Delegates Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Miss Sophie Stroeks

Cardiovascular Research Institute Maastricht (CARIM), Maastricht (Netherlands (The))

5 More presentations in this session

Presentation thumbnail
Guideline-directed medical therapy across neighbourhood socioeconomic deprivation in patients with heart failure with reduced ejection fraction: data from the Swedish Heart Failure Registry
Doctor V. Valente (Stockholm, SE)
Abstract Slides Video
Presentation thumbnail
Regional heterogeneity in adult vaccination uptake among remotely monitored heart failure patients in France: a cross-sectional survey
Professor N. Girerd (Nancy, FR)
Abstract Slides Video
Presentation thumbnail
Heart failure with preserved ejection fraction: who are our patients?
Doctor J. Fernandes (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
Twenty years of ESC heart failure guidelines: evolution of recommendation strength and evidence quality
Doctor R. Santos (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
A comparison of the social determinants and self-care behaviours of women at risk and with heart failure between 4 socio-economic groups in Ireland: An interim report from the her-heartbeat project.
Ms M. Ryder (Dublin, IE)
Abstract Slides Video

Access the full session

Session thumbnail
Socioeconomics and regional heterogeneity of heart failure

The Event

Event poster

Heart Failure 2026

9 May 2026 13:30 CET
You may be interested in
thumbnail
Congress Presentation
Prevalence of substance use disorder among patients hospitalized for heart failure
thumbnail
Congress Presentation
Long-term survival and precisions phenotyping in patients with dilated cardiomyopathy
thumbnail
Congress Presentation
Genotype-driven prognostication in dilated cardiomyopathy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources